SGHT Earnings

SGHT reported its earnings on 2026-03-04, showcasing a revenue of 20.39M against an estimate of 20.27M, resulting in a 0.57% surprise. The EPS was -0.08, surpassing the expected -0.14 by 42.86%. The stock experienced a -26.8% price change on the earnings day and a -25.88% change over the next five days, reflecting market reactions to the results.

Following SGHT's earnings announcement on 2026-03-04, the stock price moved by -26.8% on the day of the release. Over the subsequent five days, it saw a -25.88% change. Historically, SGHT's stock price tends to shift by an average of 7.65% in the 10 days leading up to earnings and 5.44% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate SGHT's annual revenue to reach 19.30M, while the EPS is projected at -0.17. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SGHT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SGHT's stock price typically moves by 7.65% in the 10 days before its earnings and 5.44% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.17 and revenue of 19.30M.

The earnings call highlights several positive developments: raised revenue guidance, reduced operating expenses, and significant market opportunities in the dry eye segment. Despite some cautious guidance and uncertainties in reimbursement and market access, the company's strategic focus and expected cost savings position it for growth. The Q&A session supports this with a generally positive sentiment from analysts, despite some vague responses from management. Overall, the positive aspects outweigh the negative, leading to a positive stock price outlook over the next two weeks.